“…Such drugs act by inhibiting the enzyme in parasitic or malignant cells. There have been several studies aimed at investigating the speci®city of the ligand binding (see for example Roth & Cheng, 1982;Baccanari & Kuyper, 1993) and extensive structural information has been obtained on a number of DHFR complexes from different species using NMR and X-ray crystallography (reviewed by Blakley, 1985;Freisheim & Matthews, 1984;Feeney, 1990Feeney, , 1996. For the enzyme from Escherichia coli, there are high-resolution crystal structures available on the enzyme alone (Bystroff & Kraut, 1991) several binary complexes Kuyper et al, 1982;Matthews et al, 1985a,b;Bystroff et al, 1990;Warren et al, 1991;Reyes et al, 1995;Lee et al, 1996;Sawaya & Kraut, 1997) and ternary complexes (Bystroff et al, 1990;Sawaya & Kraut, 1997).…”